- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
U.S. Supreme Court Upholds the ACA
The nation's highest court has upheld the ACA three times.
The U.S. Supreme Court issued a ruling this morning upholding the ACA.
The Associated Press reported that the justices, in a 7-2 vote, ruled that Texas, other Republican-led states and individuals didn’t have a right to bring their suit in federal court.
This is the third time that the Supreme Court has heard a legal challenge to the 2010 law and left the law intact
The court ruling did not take up the larger issues in the case, California v. Texas, and the question of whether one provision was legally "severable" from the rest of the sprawling healthcare legislation.
Instead, the justices decided that the plaintiffs lacked standing to bring a constitutional challenge.
Justice Stephen Breyer wrote the majority opinion, which was joined by two Trump-appointed justices, Brett Kavanaugh and Amy Coney Barrett. Justice Samuel Alito wrote a dissenting opinion, which was joined by Justice Neil Gorsuch.
"After numerous legal challenges and efforts to repeal it, the ACA stands and is as popular as it has ever been," tweeted Larry Levitt, executive vice president for health policy for the Kaiser Family Foundation.
2023 Drug Trend Report - Xevant
May 16th 2024To effectively navigate the changing pharmacy landscape and maintain a robust, cost-effective pharmacy benefit, you must understand the forces behind rising drug trend. What’s driving your costs and what can you do about it? As a leader in the PBM analytics space, we offer a unique perspective on pivotal trend drivers. Here’s what our comprehensive analysis revealed: -A surge in utilization rates across specialty and non-specialty drugs, magnified by anti-obesity therapies -Financial strain imposed by anti-inflammatory biologics and the yet-to-be-fulfilled -promise of biosimilar savings -Persistent price inflation driving higher costs year over year
Read More
